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Control of GI Arrest After DNA Damage
by Michael B. Kastan1 and Steven J. Kuerbitz1
The temporal relationship between DNA damage and DNA replication may be critical in
determining whether the genetic changes necessary for cellular transformation occur after
DNA damage. Recent characterization of the mechanisms responsible for alterations in cell-
cycle progression after DNA damage in our laboratory have implicated the p53 (tumor suppres-
sor) protein in the G, arrest that occurs after certain types of DNA damage. In particular, we
found that levels ofp53 protein increased rapidly and transiently after nonlethal doses of yirra-
diation (XRT) in hematopoietic cells with wild-type, but not mutant, p53 genes. These changes
in p53 protein levels were temporally linked to a transient GI arrest in these cells. Hemato-
poietic cells with mutant or absentp53 genes did not exhibit this G, arrest, through they contin-
ued to demonstrate a G2 arrest. We recently extended these observations of a tight correlation
between the status ofthe endogenousp53 genes and this G, arrest after XRT and this cell-cycle
alteration after XRT was then established by transfecting cells lacking endogenous p53 genes
with a wild-type gene and observing acquisition of the G1 arrest and by transfecting cells pro-
cessing endogenous wild-type p53 genes with a mutant p53 gene and observing loss of the GI
arrest after XRT. These observations and their significance for our understanding ofthe mecha-
nisms ofDNA damage-induced cellular transformation are discussed.
Transient alterations in cell-cycle progression after
DNA damage are well documented. Presumably, these
responses permit optimal repair of damage before the
cell reinitiates replicative DNA synthesis (G1 arrest)
and/or begins mitosis (G2 arrest). If replicative DNA
synthesis or mitosis occurred before repair ofthe dam-
age, then mutagenic lesions could be "fixed" and prop-
agated (1) and could contribute to the progressive
increase in genomic changes necessary for neoplastic
transformation (Fig. 1). Currently, little is known
about the cellular signals required for these cell-cycle
checkpoints after DNA damage in mammalian cells. In
yeast, the RAD9 gene product appears to be necessary
for G2 arrest after damage (2), but the factors required
for G1 arrest remain unclear.
We recently began to characterize some ofthe mech-
anisms that control cell-cycle changes in response to
DNA damage in mammalian cells (3). Using hema-
topoietic cell lines as models, we found that nonlethal
doses ofyirradiation (XRT) transiently inhibit replica-
tive DNA synthesis via both G1 and G2 arrests. We
reasoned that this inhibition of replicative DNA syn-
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thesis after XRT could result from either inhibition of
a positive regulator of DNA synthesis or stimulation
or a negative regulator. Because the p53 gene product
had been demonstrated to be a negative regulator of
DNA synthesis (4-7) and because this tumor-suppres-
sor gene is the most commonly mutated gene thus far
identified in human cancers, linkage of p53 to this
DNA damage-induced inhibition of DNA replication
was an attractive possibility.
Because the wild-type p53 gene product is a nega-
tive regulator of DNA synthesis, ifit were involved in
this pathway we would expect to see an increase in p53
protein levels (and/or functional activity) after DNA
damage.
Using either a sensitive flow cytometric assay forp53
protein expression or metabolic labeling followed by
immunoprecipitation, we observed that levels of p53
increased in ML-1 myeloblastic leukemia cells [which
have wild-type p53 genes (3)] in temporal association
with the decrease in replicative DNA synthesis after
XRT. We demonstrated that this increased p53 protein
after XRT was localized to the cell nucleus, which is
when p53 protein must be in order to be functional
(7,8). Levels of p53 protein also increased in temporal
association with a decrease in replicative DNA synthe-
sis after treatment of ML-1 cells with actinomycin D,
which, like XRT, induces DNA strand breaks. In con-
trast, p53 protein levels did not change after exposure
of ML-1 cells to cytosine arabinoside, which neither
directly damages DNA nor causes a G1 arrest.KASTANAND KUERBITZ
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FIGURE 1. Schematic representation ofalternative cellular responses to DNA damage. After DNA damage, cells might never replicate again or
might die-these two possibilities do not lead to the development ofmalignancies and are not depicted. The other two possible courses are for
the cell to repair the DNA damage before replicative DNA synthesis or for DNA replication to occur before the integrity of the DNA is
restored. Ifthe latter option occurs, replicative synthesis will use a damaged DNA template: this could lead to propagation ofgenetic abnor-
malities in daughter cells. In a premalignant cell, this latter process could contribute to the array ofgenetic changes that lead to the fully
transformed phenotype. Our data suggest that wild-type p53 protein plays a critical role in determining whether the cell follows the repair
orreplication pathway.
These results suggested that p53 protein was partic-
ipating in the cellular response to DNA damage. We
then took advantage of the known status of the p53
gene in a number of hematopoietic cell lines and fur-
ther implicated wild-type p53 protein in this Gl arrest
after XRT by demonstrating that cells with no p53
genes and cells with mutant p53 genes do not exhibit
the G1 arrest. Interestingly, however, cells with mutant
p53 genes continued to arrest in G2 after XRT.
More recently, we demonstrated that this close cor-
relation between p53 geine status and the ability to
arrest in G1 after XRT is not restricted to hematopoi-
etic cells. Adherent cells with wild-type p53 genes
(normal human fibroblasts, RKO colorectal carcinoma
cells, and U-20S osteosarcomal cells) also exhibit G,
arrest after XRT, whereas adherent cells with mutant
p53 genes (SW480 colorectal carcinoma cells and Saos
osteosarcoma cells) continue to progress though S-
phase after XRT (9). Thus, with 11 different cell types
evaluated thus far, there is a 100% concordance
between the status of the p53 gene and the ability to
arrest inG, after XRT (summarized in Table 1).
These observations established a very strong corre-
lation, but not a cause-effect relationship, between
wild-type p53 and the G1 arrest after XRT. Such a
cause-effect relationship was established by transfect-
ing a) HL60 cells, which have no endogenous p53
genes, with a wild-type p53 gene; the transfected cells
expressed low levels ofp53 protein and partially recov-
ered the G1 arrest after XRT and b) RKO colorectal
carcinoma cells, which have wild-type p53 genes, with
a dominant negative mutant p53 gene; these transfec-
tants partially lost the ability to arrest in G1 after XRT
(9). These transfection results confirmed the role of
wild-type p53 genes in the arrest of cells in G, after
XRT, thus allowing cells with wild-type p53 genes to
avoid replication ofDNA using adamaged template.
We are currently investigating the biochemical
mechanism(s) responsible for this induction ofp53 pro-
tein levels after DNA damage. Because we found that
levels of p53 mRNA do not change after XRT and
because the p53 protein levels also increase after DNA
damage induced by doses of actinomycin D that can
significantly inhibit RNA synthesis, this induction of
p53 protein appears to occur via a post-transcriptional
mechanism. In addition, treatment of irradiated cells
with caffeine inhibits both the G1 and G2 arrests and
also inhibits the increase in p53 protein; in contrast,
cycloheximide treatment (reversibly) inhibits G1, but
not G2, arrest, while also blocking the increase in p53
protein after XRT (3). These observations suggest that
certain types of DNA damage initiate a signal trans-
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Table 1. Status ofp53 gene, protein, and y-irradiation response in selected cell types.
p53 Mutant Amino acid p53 GI
Cell Lineage gene codon change proteina arrestb
NBMP Myeloid WT - - +/- +
ML-1 Myeloid WT - - + +
344 Fibroblast WT - - + +
RKO ColoCa WT - - + +
U-20S'; Osteosarcoma WT - - + +
KG-la Myeloid M/- 225 VAL-ILE
HL-60 Myeloid A -
Raji Lymphoid M/WT 213 ARG-GLN +++
RPM18402 Lymphoid MIWT 273 ARG-CYS +++
SW480 ColoCa M/- 273 ARG-HIS +++
309 PRO-SER
Saos-2(5) Osteosarcoma A -
Abbreviations: NBMP, normal bone marrow progenitor cells rapidly growing in liquid culture (only myeloid progenitor cells grow under
these conditions); M, mutant p53 gene; WT, wild-type p53 gene; A, absent p53 gene.
aRelative levels ofp53 protein; +++, high levels; +, low levels; -, no detectable protein; +/-, proliferative NBMP cells normally have no
detectable p53 protein, but express low levels after y-irradiation.
bSignificant decrease in percentage ofcells in S-phase after y-irradiation.
duction pathway that transiently increases levels of
p53 protein via a post-transcriptional mechanism,
which subsequently results in a transient inhibition of
replicative DNA synthesis. The effects of caffeine and
cycloheximide on this process further demonstrate
that exposure to non-genotoxic agents can affect this
signal transduction pathway and alter this cellular
response to DNA damage and thus increase the risk of
"fixing" mutagenic lesions. Investigations to further
characterize this signal transduction pathway are
underway.
Before these investigations, the contribution of
abnormalities in the p53 gene to tumorigenesis was
primarily attributed to the loss of an inhibitor of cellu-
lar proliferation, which thus permitted unrestricted
cell growth. This mechanism may, in fact, be very
important in cellular transformation; however, our
observations, in addition to beginning to clarify the
important components of the cell-cycle check points
after DNA damage, suggest another mechanism for
the contribution of abnormalities in the p53 gene to
tumorigenesis and genetic instability. Cells with
abnormal p53 genes do not appear to be able to effi-
ciently cease replicative DNA synthesis after (at least
with certain types of) DNA damage, despite the pres-
ence ofa damaged DNA template. Such cells would be
at increased risk for developing further genetic abnor-
malities after exposure to DNA-damaging agents. A
preneoplastic cell with an abnormal p53 gene might
therefore be at higher risk for developing the subse-
quent genetic changes necessary for expression of a
fully transformed phenotype after DNA damage than
a cell with wild-type p53 genes. Thus, the separate
observations that p53 is mutated in a high percentage
of human solid tumors and that most tumors contain
multiple, gross chromosomal abnormalities may be
more thanjust coincidence; they may be causally relat-
ed through the type ofmechanism discussed here.
In terms ofthe theme ofthis symposium, this type of
model suggests that both DNA damage and cell prolif-
eration are important contributors to the carcinogenic
process and that the relative timing of the two events
may be a critical variable. Interestingly, p53 is a heavi-
ly methylated gene [(10); Kuerbitz and Kastan, unpub-
lished results], and a high percentage ofp53 mutations
in tumors are C to T transitions (10), which could result
simply from spontaneous deamination of 5-methyl-
deoxycytidine in the DNA. Thus, genotoxic damage
need not be responsible for the p53 gene mutations
that are frequently noted in tumors, and increased cell
proliferation alone could increase the chance of such
spontaneous deaminations resulting in C to T transi-
tions. According to our model, once activating muta-
tions have occurred in the p53 gene, whether by geno-
toxic damage or by spontaneous deamination and a C
to T transition, the cell would be at increased risk for
developing the other genetic lesions required for a
fully transformed phenotype after exposure to DNA
damaging agents.
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